Nicholas Hoffman & Company LLC. Raises Stock Holdings in Solventum Corporation $SOLV

Nicholas Hoffman & Company LLC. raised its position in shares of Solventum Corporation (NYSE:SOLV) by 113.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,294 shares of the company’s stock after buying an additional 9,188 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in Solventum were worth $1,129,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in SOLV. Independent Franchise Partners LLP increased its holdings in Solventum by 27.2% during the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after purchasing an additional 2,758,174 shares during the period. Norges Bank bought a new stake in shares of Solventum in the 4th quarter worth approximately $147,467,000. Diamond Hill Capital Management Inc. grew its position in shares of Solventum by 152.2% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock worth $167,119,000 after buying an additional 1,272,921 shares during the last quarter. Boston Partners increased its stake in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Solventum by 20.0% during the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares during the period.

Solventum Price Performance

SOLV opened at $76.24 on Wednesday. The stock has a fifty day simple moving average of $75.76 and a two-hundred day simple moving average of $74.38. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The company has a market cap of $13.20 billion, a price-to-earnings ratio of 9.34, a price-to-earnings-growth ratio of 1.20 and a beta of 0.66. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company’s quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SOLV. Piper Sandler cut their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Weiss Ratings lowered shares of Solventum from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, June 26th. Rothschild & Co Redburn initiated coverage on shares of Solventum in a research note on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price on the stock. Wells Fargo & Company reduced their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Finally, Wedbush began coverage on shares of Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target for the company. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $83.73.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.